| Name | Title | Contact Details |
|---|
NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RNL BioStar Inc. is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaVo Dental Corporation is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.